Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983185 | 0.99 | PLA2G4B (0.65) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL2312866 | 0.84 | PLA2G4B (0.83) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL4253646 | 0.83 | PLA2G4B (0.81) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL4373447 | 0.83 | PLA2G4B (0.86) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL4366698 | 0.83 | PLA2G4B (0.86) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL13131233 | 0.82 | GSK3B (0.64) | PTPN1GSK3BNPC1RAB9ADPP4 | |
| SCHEMBL4253642 | 0.82 | PLA2G4B (0.66) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL11727340 | 0.82 | L3MBTL1 (0.72) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL7502356 | 0.82 | PLA2G4B (0.66) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 | |
| SCHEMBL9044748 | 0.82 | PLA2G4B (0.66) | PLA2G4BFFAR1NR1H4S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007092190-A2 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | PLA2G4B 57/4885FFAR1 30/4885NR1H4 589/4885 |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | PLA2G4B 57/4885FFAR1 30/4885NR1H4 589/4885 |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | PLA2G4B 57/4885FFAR1 30/4885NR1H4 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.